Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher S Ambrose

Showing results (1-10 of 160) with videos related to

Pageof 16
Sort By:
Expert Review of Vaccines|August 23, 2011
Efficacy and correlates of protection for cell culture-derived and egg-derived inactivated influenza vaccines in younger adultsChristopher S Ambrose
The Pediatric Infectious Disease Journal|February 11, 2017
Statistical Power to Detect an Association Between Guideline-based Palivizumab Administration and Hospitalizations for Respiratory Syncytial Virus InfectionsChristopher S Ambrose
Pediatrics|December 3, 2014
Severe RSV disease in preterm infants born at 29 to 35 weeks' gestation in the United StatesChristopher S Ambrose
Human Vaccines & Immunotherapeutics|March 20, 2012
Use of intranasal live attenuated influenza vaccine in individuals with asthma or a history of wheezingChristopher S Ambrose
Health Science Reports|January 10, 2019
Is it RSV?Christopher S Ambrose
Vaccine|December 25, 2012
The safety and effectiveness of self-administration of intranasal live attenuated influenza vaccine in adultsChristopher S Ambrose, Xionghua Wu
Human Vaccines|July 26, 2011
Factors associated with increased vaccination in 2009 H1N1 school-located influenza vaccination programsChristopher S Ambrose, Frangiscos Sifakis
Pediatrics|April 3, 2014
Clarifying costs and benefits of respiratory syncytial virus immunoprophylaxisKimmie McLaurin, Christopher S Ambrose
The Pediatric Infectious Disease Journal|May 18, 2011
Evidence of homosubtypic but not heterosubtypic immunity in young children following wild-type influenza illnessChristopher S Ambrose, Xionghua Wu
Human Vaccines & Immunotherapeutics|January 19, 2012
The rationale for quadrivalent influenza vaccinesChristopher S Ambrose, Myron J Levin
Pageof 16

Showing results (1-10 of 160) with videos related to

Sort By:
Pageof 16
Expert Review of Vaccines|August 23, 2011
Efficacy and correlates of protection for cell culture-derived and egg-derived inactivated influenza vaccines in younger adultsChristopher S Ambrose
The Pediatric Infectious Disease Journal|February 11, 2017
Statistical Power to Detect an Association Between Guideline-based Palivizumab Administration and Hospitalizations for Respiratory Syncytial Virus InfectionsChristopher S Ambrose
Pediatrics|December 3, 2014
Severe RSV disease in preterm infants born at 29 to 35 weeks' gestation in the United StatesChristopher S Ambrose
Human Vaccines & Immunotherapeutics|March 20, 2012
Use of intranasal live attenuated influenza vaccine in individuals with asthma or a history of wheezingChristopher S Ambrose
Health Science Reports|January 10, 2019
Is it RSV?Christopher S Ambrose
Vaccine|December 25, 2012
The safety and effectiveness of self-administration of intranasal live attenuated influenza vaccine in adultsChristopher S Ambrose, Xionghua Wu
Human Vaccines|July 26, 2011
Factors associated with increased vaccination in 2009 H1N1 school-located influenza vaccination programsChristopher S Ambrose, Frangiscos Sifakis
Pediatrics|April 3, 2014
Clarifying costs and benefits of respiratory syncytial virus immunoprophylaxisKimmie McLaurin, Christopher S Ambrose
The Pediatric Infectious Disease Journal|May 18, 2011
Evidence of homosubtypic but not heterosubtypic immunity in young children following wild-type influenza illnessChristopher S Ambrose, Xionghua Wu
Human Vaccines & Immunotherapeutics|January 19, 2012
The rationale for quadrivalent influenza vaccinesChristopher S Ambrose, Myron J Levin
Pageof 16